Skip to content
Search

Latest Stories

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

In 2023/24, over 3 million patients received NHS prescriptions where a prepayment certificate exemption was applied.

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.


NHSBSA analysis found that these patients could have spent £817 million in prescription charges if they had not used a PPC.

A PPC allows patients to get as many NHS prescriptions as they need for a set price over a fixed period, helping those who require regular medication to save money.

With the current prescription charge in England set at £9 per item, a three-month PPC costs £29.10, while a 12-month PPC is available for £104. Patients who purchase two prescriptions per month could save over £20 each month with a three-month PPC or more than £110 annually with a 12-month certificate.

Key Findings from the Report

The NHSBSA noted that this analysis is based on NHS prescriptions dispensed in the community and submitted to the authority for reimbursement.

In 2023/2024, more than two-thirds (2.1 million) of PPCs issued were 12-month certificates, while 936,000 were three-month PPCs.

NHSBSA estimated that if all these patients had purchased a 12-month PPC, they could have saved approximately £451 million.

The latest analysis found that around 566,000 HRT PPCs were issued in 2023/24, with higher rates issued in less deprived areas.

Without an HRT PPC, these patients could have faced £20.2 million in prescription charges.

Assuming each patient paid £19.30 for an HRT PPC, they collectively saved an estimated £11.2 million.

The HRT PPC was launched in April 2023, with 131,000 certificates being issued in the first month.

The report also identified missed savings opportunities for eligible patients who did not purchase a PPC.

It estimated that around 872,000 patients could have saved around £35 million (£41 each on average) with a 12-month PPC, while 286,000 patients could have potentially saved around £8 million (£27 each on average) with an HRT PPC, which covers 12 months.

The NHSBSA plans to publish this report annually to provide insights into PPC uptake and estimated patient savings.

The NHSBSA website also highlights that the number of customers applying online for a PPC has now surpassed one million, contributing to NHS savings of more than £390,000.

Patients can apply for a digital PPC online at www.nhsbsa.nhs.uk/ppc or via a registered pharmacy.

More For You

Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Three pharmacists named in NIHR’s latest cohort of senior investigators

L-R: Professor David Alldred; Professor Rachel Elliott and Professor Ian Maidment.

Three pharmacists appointed as NIHR senior investigators

The National Institute for Health and Care Research (NIHR) has announced its latest cohort of senior investigators, including three distinguished pharmacists.

David Alldred, professor of medicines use and safety at the University of Leeds; Rachel Elliott, professor of health economics at the University of Manchester; and Ian Maidment, professor in clinical pharmacy at Aston University, have been named in the list of 39 new appointments, alongside 19 reappointed senior investigators.

Keep ReadingShow less